Dermal Irritation, Sensitization, and Safety of Fixed-Dose Triple-Combination Clindamycin Phosphate 1.2%/Benzoyl Peroxide 3.1%/Adapalene 0.15% Gel in Healthy Participants
Main Article Content
Keywords
Tolerability, Irritation, CIPT, RIPT, Retinoid, BPO, Adapalene, Clindamycin, Antiobiotic, Combination
Abstract
Introduction: IDP-126 polymeric mesh gel (clindamycin phosphate 1.2%/benzoyl peroxide [BPO] 3.1%/adapalene 0.15%) is the first triple-combination, fixed-dose topical acne product in development and it addresses major acne pathophysiological processes. IDP-126 demonstrated superior efficacy to vehicle and component dyads, with good safety/tolerability in a phase 2 study of participants with moderate-to-severe acne. The objectives of this study were to assess dermal irritation/sensitization and safety of IDP-126 gel in two phase 1 studies and to compare irritancy of IDP-126 gel and commercially available BPO 2.5%/adapalene 0.3% gel in one phase 1 study of healthy participants.
Methods: Two phase 1, randomized, evaluator-blinded, within-participant, dermal safety studies enrolled healthy participants aged ≥18 years (N=234, repeat insult patch test [RIPT]; N=45, cumulative irritation patch test [CIPT]). Patches were applied to the upper back multiple times over 6-8 weeks (RIPT) or every 24 hours for 21 days (CIPT). Patches contained: IDP-126 gel, vehicle gel, saline 0.9% (RIPT/CIPT), sodium lauryl sulfate (SLS) 0.5% (CIPT), or branded BPO 2.5%/adapalene 0.3% gel (CIPT). Participants in each study received all treatments. Endpoints comprised sensitization potential (RIPT), mean cumulative/total irritation scores, and treatment-emergent adverse events (TEAEs).
Results: Overall, irritation with IDP-126 was moderate and not clinically significant. CIPT: IDP-126 was “moderately irritating” (mean score: 1.29), which was significantly less irritating than BPO/adapalene (1.96; P<0.001), statistically similar to SLS (1.17), and more irritating than saline or vehicle (~0.30; P<0.001). RIPT: no participants had investigator-confirmed sensitization to any treatments. In both studies, no TEAEs were related to treatment.
Conclusions: In two phase 1 studies, fixed-dose, triple-combination clindamycin phosphate 1.2%/ BPO 3.1%/adapalene 0.15% polymeric mesh gel had moderate irritancy and no confirmed sensitization in healthy participants. Additionally, IDP-126 demonstrated significantly less irritation versus commercially available, branded BPO 2.5%/adapalene 0.3% gel. IDP-126 demonstrated good safety/tolerability, mirroring the phase 2 study results.
Funding: Ortho Dermatologics
References
2. Nguyen, H.L. Clin Rev Allergy Immunol. 2019;56(1):41-59.
3. Foti, C. Dermatol Ther. 2015;28(5):323-9.
4. Stein Gold, L. J Am Acad Dermatol. 2022;87(3):sAB50.
5. Jordan, W.P. Contact Dermatitis. 1980;6(2):151-2.
6. Berger, R.S. J Toxicol, Cutan Ocul Toxicol. 1982;1(2):109-115.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.